<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624712</url>
  </required_header>
  <id_info>
    <org_study_id>ZGynO_DENOVA</org_study_id>
    <nct_id>NCT03624712</nct_id>
  </id_info>
  <brief_title>Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms</brief_title>
  <official_title>Prospective, Tricentric Open Trial on the Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Homburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of clinical, therapeutic and prognostic relevance of new experimental results as
      well as optimization of therapeutic models and development of a new algorithm for therapeutic
      plan and therapy in patients with uterine neoplasm
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CTC and DTC analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Counting the number of tumor cells in blood and bone marrow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of HPV types by DNA tests in peripheral blood, bone marrow, sentinel-lymph node, cervical-, endometrial- and myometrial-tissue, intraperitoneal wash fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA</measure>
    <time_frame>12 months</time_frame>
    <description>Determination of DNA in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Douglas cytology</measure>
    <time_frame>12 months</time_frame>
    <description>Intraperitoneal wash fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteomic analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of proteins by mass spectrometry in removed uterine and sentinel lymph node tissue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sentinel lymph nodes</measure>
    <time_frame>12 months</time_frame>
    <description>Number of detectable lymph nodes by Tc99m- and indocyanine green-labeling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral nerve conduction velocity</measure>
    <time_frame>12 months</time_frame>
    <description>Intra- and interindividual comparison of N. obturatorius, N. pudendus between pre an post radical gynecological surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urodynamic- cystomanometry between pre an post radical gynecological surgeryuroflowmetry</measure>
    <time_frame>12 months</time_frame>
    <description>pressur/volume relationship</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTC and DTC analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Identification and quantification of genetic variants and mutations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urodynamic- urethral pressure profile between pre an post radical gynecological surgeryuroflowmetry</measure>
    <time_frame>12 months</time_frame>
    <description>cm H20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urodynamic- uroflowmetry between pre an post radical gynecological surgeryuroflowmetry</measure>
    <time_frame>12 months</time_frame>
    <description>rate of flow of urine</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">580</enrollment>
  <condition>Uterine Neoplasms</condition>
  <arm_group>
    <arm_group_label>uterine neoplasms</arm_group_label>
    <description>Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>uterine neoplasms</intervention_name>
    <description>Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection</description>
    <arm_group_label>uterine neoplasms</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with operable or inoperable uterine malignancy (cervical cancer, endometrial cancer,
        sarcoma)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed uterine malignancy ( cervical cancer, endometrial cancer, sarcoma)

          -  If operable: surgical primary therapy: laparoscopic/robot-assisted or open radical
             gyneco-oncological surgery

          -  Written consent

          -  Willingness and ability to participate in all study-specific procedures

          -  Age â‰¥ 18 years

        Exclusion Criteria:

          -  Severe and acute general disease in the last 4 weeks

          -  Acute or chronic psychiatric disorders

          -  Other factors questioning study participation (e.g. acute psychosocial stress,
             insufficient understanding of nature and consequences of the study, inadequate skills
             of the German language)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Department of Women's Health</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Linneweh, Dr</last_name>
      <phone>+4970712982211</phone>
      <email>miriam.linneweh@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

